Diligence memo · auto-generated · as of July 2, 2026
Cynapsus Therapeutics Inc.
Cynapsus Therapeutics Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Cynapsus Therapeutics Inc. operates in Pharmaceuticals, based in TORONTO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cynapsus Therapeutics Inc. has raised $45M in disclosed capital across 10 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $17M on 2015-03-31.
Most recent recorded round closed around 2015-03-31.
Valuation (modeled)modeled
Provath models Cynapsus Therapeutics Inc. at approximately $570M (range $35M–$2.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.84× the median modeled value of Series B Pharmaceuticals companies in 2013–2015 (42 peers) — value vs value, same stage and era. Within the normal band (84% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 60 months.
Last raise 11.3 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 80% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 82% of those peers.
Closest niche peers: Lipocine Inc., CARDEAS PHARMA Corp, CoLucid Pharmaceuticals, Inc., Emisphere Technologies Inc, Vasculox, Inc..
Peoplefiled
22 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.